High on innovation, rising demand and rejuvenated confidence to translate opportunities into success, the Indian pharmaceutical industry, which is among the top three in terms of volume globally, is growing leaps and bounds. By an estimate, the industry is all set to expand at a Compound Annual Growth Rate (CAGR) of 16 per cent to $55 billion by 2020. Much of this growth will depend on Indian pharma companies’ capacity to adopt Information Technology to drive their productivity, improve efficiency and maintain cost effectiveness.

In view of increased digital adoption, it is expected that Healthcare Information Technology (IT) market would expand more than 1.5 times by 2020 from its current value of $1 billion to meet the demand from pharma industry as well as other vertical of the healthcare sector….[Read More]


Future Pharma For One World! Be a Global Leader in the Pharma

Past Partners in our Summits

eHealth 2016 Conferences Videos

Social Footprints

Facebook Likes
Linkedin Followers
Twitter Followers
Our Conferences

Powered By

RSS Latest on eHEALTH Pharma

  • Glenmark initiates clinical investigation for respiratory drug
    Global pharmaceutical major Glenmark Pharmaceuticals has received the US Food and Drug Administration (USFDA) approval for the company’s Investigational New Drug (IND) application to initiate a first-in-human study of GBR 310, a proposed biosimilar candidate for Xolair which is used to treat persistent asthma in patients 6 years of age or older. “This marks the […]
  • Zydus gets USFDA approval for anti-hypertensive tablets
    Indian pharmaceutical major Zydus Cadila has received final nod for its anti-hypertensive drug Olmesartan Medoxomil from USFDA, the company said in a BSE filing on Tuesday. The drug will be produced at the group’s formulations manufacturing facility at the pharma SEZ in Ahmedabad. The estimated sales of Olmesartan is $982 million. With this latest approval, […]
  • Jubiliant Life gets ANDA approval for its hypertension drug
    Jubiliant Life Sciences Ltd has received the final Abbreviated New Drug Application (ANDA) approval for its drug Olmesartan Medoxomil, the generic version of Benicar of Daiichi Sanyo, which is used for treating hypertension. “This is the second approval that we have received from the USFDA during the current financial year,” the company said in a […]
  • India to impose anti-dumping duty on Amoxycillin from China
    The Directorate General of Anti-dumping and Allied Duties (DGAD) has recommended imposition of anti-dumping duty on the import of Amoxycillin, a semi-synthetic antibiotic which is used to reduce the development of drug-resistant bacteria, from China. The recommendation came after Aurobindo Pharma Ltd, a domestic producer of the product in India, had filed an application before […]
  • Aurobindo Pharma’s API expansion to create 600 new jobs
    Leading Indian pharmaceutical research company Aurobindo Pharma is planning to expand its Active Pharmaceuticals Ingredients (API) manufacturing capacity, providing direct job opportunity to 300 people and indirect employment to about 600 people, a media report said. The company will invest Rs 250 crore to increase API manufacturing capacity of its plant in Ranasthalam mandal in […]

Know More About Pharma CIO 2017